Log in
(Ad)
A brand-new technology - code named "Halo-Fi" - could kill off your overpriced cable company for good... beaming lightning-fast internet to your home for an estimated $7 a month.

This is undoubtedly the beginning of the end for "Big 3" internet providers.

Forward-thinking investors in Halo-Fi are lining up to get rich before January 30th.

NASDAQ:FTSV - Forty Seven Stock Price, Forecast & News

$45.74
+4.59 (+11.15 %)
(As of 01/21/2020 03:47 AM ET)
Today's Range
$42.31
Now: $45.74
$49.50
50-Day Range
$12.65
MA: $35.64
$45.74
52-Week Range
$5.53
Now: $45.74
$49.50
Volume1.80 million shs
Average Volume560,835 shs
Market Capitalization$1.93 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.53
Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FTSV
CUSIPN/A
CIKN/A
Phone650-352-4150

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.29 per share

Profitability

Net Income$-70,370,000.00

Miscellaneous

Employees57
Market Cap$1.93 billion
Next Earnings Date3/26/2020 (Estimated)
OptionableNot Optionable

Receive FTSV News and Ratings via Email

Sign-up to receive the latest news and ratings for FTSV and its competitors with MarketBeat's FREE daily newsletter.


(Ad)


Located just 25 miles from Cleveland... is a supergreenhouse unlike anything we've ever seen. Listed at over 1.4 million sq ft, (the size of 9 full-sized Costco warehouses), this marijuana grow house is capable of producing over 341,000 pounds of weed/year! And very soon it will come online and could turn a tiny 60-cent pot company into the dominator in the white-hot weed market.

Forty Seven (NASDAQ:FTSV) Frequently Asked Questions

What is Forty Seven's stock symbol?

Forty Seven trades on the NASDAQ under the ticker symbol "FTSV."

How were Forty Seven's earnings last quarter?

Forty Seven Inc (NASDAQ:FTSV) issued its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.38). The firm earned $15.68 million during the quarter, compared to analysts' expectations of $15.80 million. View Forty Seven's Earnings History.

When is Forty Seven's next earnings date?

Forty Seven is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Forty Seven.

What price target have analysts set for FTSV?

11 Wall Street analysts have issued 1 year target prices for Forty Seven's shares. Their forecasts range from $18.00 to $55.00. On average, they anticipate Forty Seven's share price to reach $39.45 in the next twelve months. This suggests that the stock has a possible downside of 13.7%. View Analyst Price Targets for Forty Seven.

What is the consensus analysts' recommendation for Forty Seven?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Forty Seven in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Forty Seven.

What are Wall Street analysts saying about Forty Seven stock?

Here are some recent quotes from research analysts about Forty Seven stock:
  • 1. According to Zacks Investment Research, "Forty Seven, Inc. is a clinical-stage immuno-oncology company. It focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The company's product candidate consists of 5F9, is an IgG4 monoclonal antibody against CD47 which is designed to interfere with recognition of CD47 by the SIRP? receptor on macrophages. Forty Seven, Inc. is based in CA, United States. " (12/25/2019)
  • 2. Mizuho analysts commented, "We initiate coverage of FTSV with a Buy rating and $18 PT. We like the speed- to-market program for 5F9 (pivotal readout by 4Q20). We also like the pursuit of a novel mechanism in immuno-oncology, innate immunity via CD47. FTSV has cash into 2021 and readouts that should serve as valuation inflection points." (9/11/2019)

Has Forty Seven been receiving favorable news coverage?

Media stories about FTSV stock have been trending positive on Tuesday, InfoTrie reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Forty Seven earned a news impact score of 3.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the next several days. View News Stories for Forty Seven.

Are investors shorting Forty Seven?

Forty Seven saw a decrease in short interest in December. As of December 13th, there was short interest totalling 2,050,000 shares, a decrease of 9.3% from the November 28th total of 2,260,000 shares. Based on an average daily trading volume, of 658,400 shares, the short-interest ratio is presently 3.1 days. Approximately 8.9% of the company's shares are short sold. View Forty Seven's Current Options Chain.

Who are some of Forty Seven's key competitors?

What other stocks do shareholders of Forty Seven own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Forty Seven investors own include Sorrento Therapeutics (SRNE), Energy Transfer LP Unit (ET), Bristol-Myers Squibb (BMY), Amarin (AMRN), TG Therapeutics (TGTX), AT&T (T), Clovis Oncology (CLVS), Cronos Group (CRON), GlycoMimetics (GLYC) and Intercept Pharmaceuticals (ICPT).

Who are Forty Seven's key executives?

Forty Seven's management team includes the folowing people:
  • Dr. Mark A. McCamish, Pres, CEO & Director (Age 66)
  • Dr. Craig S. Gibbs, Chief Bus. Officer (Age 56)
  • Dr. Chris H. Takimoto M.D., Ph.D., Chief Medical Officer (Age 60)
  • Mr. Mark Chao, Founder & VP of Clinical Devel.
  • Mr. Jens-Peter Volkmer, Founder and VP of Research & Early Devel.

When did Forty Seven IPO?

(FTSV) raised $100 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity, BTIG and Oppenheimer were co-managers.

How do I buy shares of Forty Seven?

Shares of FTSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Forty Seven's stock price today?

One share of FTSV stock can currently be purchased for approximately $45.74.

How big of a company is Forty Seven?

Forty Seven has a market capitalization of $1.93 billion. The company earns $-70,370,000.00 in net income (profit) each year or ($3.75) on an earnings per share basis. Forty Seven employs 57 workers across the globe.View Additional Information About Forty Seven.

What is Forty Seven's official website?

The official website for Forty Seven is http://www.fortyseveninc.com/.

How can I contact Forty Seven?

Forty Seven's mailing address is 1490 O`BRIEN DRIVE SUITE A, MENLO PARK CA, 94025. The company can be reached via phone at 650-352-4150 or via email at [email protected]


MarketBeat Community Rating for Forty Seven (NASDAQ FTSV)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  126 (Vote Outperform)
Underperform Votes:  112 (Vote Underperform)
Total Votes:  238
MarketBeat's community ratings are surveys of what our community members think about Forty Seven and other stocks. Vote "Outperform" if you believe FTSV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FTSV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2020 by MarketBeat.com Staff

Featured Article: Portfolio Manager

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel